Alembic announces USFDA Final Approval for Carbamazepine Tablets USP, 200 mg
Carbamazepine Tablets USP, 200 mg have an estimated market size of US$ 32 million for twelve months ending December 2024 according to IQVIA
Carbamazepine Tablets USP, 200 mg have an estimated market size of US$ 32 million for twelve months ending December 2024 according to IQVIA
The EIR was issued following an inspection of the facility conducted from June 10 to June 13, 2024
Genomics is transforming the future of modern medicine and treatment modalities across specialties
Aarti Pharmalabs becomes 6th Indian Pharma/CDMO to earn SBTi approval for all 3 Scopes since 2022 demerger
Feldan's proprietary Shuttle peptide technology enables the efficient and targeted delivery of biomolecules into cells, unlocking new therapeutic possibilities
This change is subject to the approval of the shareholders of the company, the Ministry of Corporate Affairs and other statutory and regulatory authorities,
The discontinuation decision is only on the basis of commercial reasons and is not due to efficacy or safety reasons
Centre for Continuous Manufacturing and Advanced Crystallisation (CMAC) aims to accelerate the digital transformation of CMC development and manufacturing approaches
More than 40 types of Amyloid proteins are discovered till date
YESAFILI, a vascular endothelial growth factor (VEGF) inhibitor, is used to treat several different types of ophthalmology conditions
Subscribe To Our Newsletter & Stay Updated